Fabrication of solid lipid nanoparticles-based patches of paroxetine and their ex-vivo permeation behaviour
Source abstract
Abstract
Paroxetine is not suitable for oral administration due to its extensive first-pass metabolism, thus resulting in less bioavailability. This study aimed to prepare novel paroxetine-loaded solid lipid nanoparticles (SLNs) based sustained-release transdermal patches to overcome these problems by enhancing drug absorption and bioavailability. Nine formulations of paroxetine SLNs were prepared by the hot melt-homogenization method using different concentrations of glycerol monostearate (Kolliwax) and Tween 80. Then these prepared SLNs were incorporated in a matrix type transdermal patch having a matrix of ethyl cellulose and polyvinyl pyrrolidone in 3:2 with polyvinyl alcohol. The SLNs showed a particle size range of 113-230 nm and an entrapment efficiency of 85.14%. The SLNs showed sustained paroxetine release (77.86-95.63% release) up to 48 h. FTIR studies showed no interaction between drug and formulation components. Paroxetine is evenly distributed in an amorphous form in SLNs, as demonstrated by DSC as well as PXRD analysis. SLNs formulated patches showed higher drug permeation through the skin than drug-based transdermal patches., Draize patch test revealed no sign of erythema after applying paroxetine-loaded SLN patches (score 0) as observed with the marketed product. The developed SLNs based transdermal patches showed increased permeability and sustained release behaviour.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Dermatology and Skin Diseases · Essential Oils and Antimicrobial Activity
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Bahawalpur, Pakistan
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates
College of Pharmacy, Fatima College of Health Sciences, Abu Dhabi, United Arab Emirates
Department of Chemistry, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, Pakistan
Department of Pharmacy, COMSATS University Islamabad, Lahore Campus, Lahore, Pakistan
References (51)
Show source-provided references
1. 10.2147/IJN.S6714710.2147/IJN.S67147 ↗
2. Abousamra MM, Mohsen MA. Solid lipid nanoparticles and nanostructureed lipid carriers of tolnaftate: design, optimization and in-vitro evaluation measurement. Int J Pharm Pharm Sci. 2016;10:100.
3. 10.1016/j.ejps.2012.05.01010.1016/j.ejps.2012.05.010 ↗
4. Paroxetine Medscape. 2022. Available from: https://reference.medscape.com/drug/paxil-brisdelle-paroxetine-342959
5. Shah R · J Phys Sci · 2014 · 25 · 59
6. 10.1155/2018/290862610.1155/2018/2908626 ↗
7. 10.1016/j.ijpharm.2013.01.01610.1016/j.ijpharm.2013.01.016 ↗
8. Prajapati P · Int J Pharma Bio Sci · 2014 · 3 · 1019
9. 10.1208/s12249-011-9727-610.1208/s12249-011-9727-6 ↗
10. 10.4103/0250-474X.5728210.4103/0250-474X.57282 ↗
11. 10.1208/pt080102410.1208/pt0801024 ↗
12. 10.15171/apb.2015.04310.15171/apb.2015.043 ↗
13. 10.1016/S0939-6411(00)00087-410.1016/S0939-6411(00)00087-4 ↗
14. 10.1016/j.ejpb.2004.02.01710.1016/j.ejpb.2004.02.017 ↗
15. 10.1111/j.1742-1241.2009.02052.x10.1111/j.1742-1241.2009.02052.x ↗
16. 10.1016/j.ejpb.2006.03.00910.1016/j.ejpb.2006.03.009 ↗
17. Bhalekar MR. · Asian J Pharm · 2016 · 10 · 45
18. 10.4103/0975-1483.8376510.4103/0975-1483.83765 ↗
19. Onal A · J AOAC Int · 2005 · 88 · 49010.1093/jaoac/88.2.490 ↗
20. Abdellatif AA · J Pharm Innov · 2018 · 14 · 1
21. 10.1016/j.ejpb.2018.03.00410.1016/j.ejpb.2018.03.004 ↗
22. 10.1111/jphp.1213610.1111/jphp.12136 ↗
23. Idrees A · Acta Pol Pharm · 2014 · 71 · 287
24. 10.1002/jps.2005810.1002/jps.20058 ↗
25. Rajabalaya R · Asian J Pharm Sci · 2008 · 3 · 30
26. Ayesha N. · J Drug Deliv Therapeut · 2019 · 9 · 295
27. Lin Y-K · Int J Nanomed · 2010 · 5 · 117
28. 10.1208/pt080100210.1208/pt0801002 ↗
29. 10.3109/08982104.2015.111749010.3109/08982104.2015.1117490 ↗
30. 10.2174/15672010777931476710.2174/156720107779314767 ↗
31. Bagchi A, Dey BK. Formulation, in-vitro evaluations and skin irritation study of losartan potassium transdermal patches. Iran J Pharm Sci. 2010; 6: 163–170.
32. Draize JH. · J Pharmacol Exp Ther · 1944 · 82 · 377
33. 10.1016/j.ijpharm.2020.11931210.1016/j.ijpharm.2020.119312 ↗
34. 10.1016/S0168-3659(01)00354-610.1016/S0168-3659(01)00354-6 ↗
35. Kumar PP · IOSR J Pharm · 2012 · 2 · 23
36. 10.1016/S0169-409X(00)00118-610.1016/S0169-409X(00)00118-6 ↗
37. Nasiri F · Drug Dev Ind Pharm · 2020 · 1
38. 10.1007/s11095-007-9234-310.1007/s11095-007-9234-3 ↗
39. 10.1208/pt080410410.1208/pt0804104 ↗
40. 10.1016/j.jconrel.2004.01.00510.1016/j.jconrel.2004.01.005 ↗
41. 10.3109/10717544.2010.48325210.3109/10717544.2010.483252 ↗
42. Cozar I · J Mol Struct · 2011 · 993 · 24310.1016/j.molstruc.2010.12.020 ↗
43. Weiseng N · J Polym Environ · 2018 · 26 · 288110.1007/s10924-017-1175-2 ↗
44. Fu X · RSC Adv · 2015 · 5 · 6888110.1039/C5RA11842E ↗
45. 10.1208/s12249-009-9199-010.1208/s12249-009-9199-0 ↗
46. 10.1016/j.ijbiomac.2015.12.07710.1016/j.ijbiomac.2015.12.077 ↗
47. 10.1080/03639045.2016.122056310.1080/03639045.2016.1220563 ↗
48. 10.1002/adfm.20090151210.1002/adfm.200901512 ↗
49. Sugi K · Chem Pharm Bull · 2000 · 48 · 52910.1248/cpb.48.529 ↗
50. 10.1016/j.jddst.2017.08.01310.1016/j.jddst.2017.08.013 ↗
51. 10.2147/IJN.S2582510.2147/IJN.S25825 ↗